An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants

Exclusion Criteria

• •Women who are of childbearing potential or breastfeeding.
• •Any significant acute or chronic illness.
• •History of gastroesophageal reflux disease, dyspepsia, protracted nausea or chronic diarrhea.
• •History of upper gastrointestinal ulcer disease within 6 months or current symptomatic or recent gastrointestinal disease that could impact absorption of study treatment.
• •Abnormal renal profile and/or hematuria (if male) within 3 months of study start.
• •History or evidence of abnormal bleeding and/or coagulation disorder and/or evidence of coagulopathy, prolonged or unexplained clinically significant bleeding, or frequent unexplained bruising or thrombus formation, or a history of spontaneous bleeding.
• •Any major surgery within 4 weeks of study treatment administration or planned within 2 weeks after completion of the study.
• •Donation of blood to a blood bank or in a clinical study (except screening or follow-up visit) within 4 weeks of study treatment administration (within 2 weeks for plasma only).
• •Blood transfusion within 3 months of study treatment administration.
• •Use of tobacco- or nicotine-containing products (including, but not limited to cigarettes, pipes, cigars, e-cigarettes, chewing tobacco, nicotine patches, nicotine lozenges or nicotine gum) within 6 months prior to study treatment administration.
• •History of allergy to aspirin or related compounds.